Pharos iBio Co.
Latest round
- Series C
Last raised
- Jun 2021
Total raised
- $36M
Investors
- 14
About Pharos iBio Co.
, Ltd. engages in the development of new drugs specializing in the treatment of rare incurable diseases based on big data and AI technologies., Ltd. signed a contract for exclusive development of Acute Myeloid Lekemia (AML) therapeutics technology. In 2017, the company started preclinical study of PHI-101. In 2019, TGA in Australia granted PHI-101 phase 1 clinical trials. In 2020, the company engaged in the joint research and technology agreement with Yonsei University health system and established a subsidiary in USA. The company's CEO is Jeonghyeok Yun. It has overseas subsidiaries in the USA and Australia., Ltd.4 million shares at KRW 14,000 per share, within the expected price range of KRW 14,000 and KRW 18,000 on the KOSDAQ., Ltd. engages in R&D of new drug treatments for rare incurable disease using AI new drug development platform. The company calls its platform as Chemivesre platform, which can be used in all fields of discovery in the new drug development stage., Ltd. has developed several different kinds of platforms such as PHI-101-001, a treatment drug for refractory/recurrent Acute Myelogenous Leukemia (AML), PHI-101-002, a treatment for platinum-resistant/refractory ovarian cancer, etc., Ltd. plans to be listed in the KOSDAQ by the end of 2021.
Who invested in Pharos iBio Co.
14 investors across 3 rounds
See all investors in Pharos iBio Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Pharos iBio Co.
Who invested in Pharos iBio Co.?
Pharos iBio Co. has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pharos iBio Co. raised?
Pharos iBio Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Pharos iBio Co. last raise money?
Pharos iBio Co.'s most recent round on record is a Series C, in Jun 2021.
What does Pharos iBio Co. do?
Pharos iBio Co. is a biotechnology company.
Where is Pharos iBio Co. headquartered?
Pharos iBio Co. is headquartered in Anyang, South Korea.
Which VCs invest in companies like Pharos iBio Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Pharos iBio Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Pharos iBio Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.